Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

1177

Clasificación en acciones #1744
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Precio por acción
$0.69080164
Capitalización bursátil
$12.30B
Cambio (1 día)
2.86%
Cambio (1 año)
-27.78%
País
HK
Comercio Sino Biopharmaceutical Limited (1177)

Categoría

Healthcare
Historial de dividendos de Sino Biopharmaceutical Limited (1177)
Sino Biopharmaceutical Limited (símbolo bursátil: 1177) realizó un total de 69 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $0.70
Rentabilidad por dividendo (TTM): 0.0229
Pagos de dividendos de Sino Biopharmaceutical Limited (1177) desde 2004 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
2026 (TTM) $0.05 -44.44%
2025 $0.09 50.00%
2024 $0.06 -25.00%
2023 $0.08 -20.00%
2022 $0.1 150.00%
2021 $0.04 -24.95%
2020 $0.0533 33.58%
2019 $0.0399 12.39%
2018 $0.0355 13.78%
2017 $0.0312 55.22%
2016 $0.0201 128.41%
2015 $0.0088 -53.93%
2014 $0.0191 28.19%
2013 $0.0149 24.17%
2012 $0.012 -49.15%
2011 $0.0236 0.00%
2010 $0.0236 214.67%
2009 $0.0075 19.05%
2008 $0.0063 -25.88%
2007 $0.0085 26.87%
2006 $0.0067 -59.64%
2005 $0.0166 730.00%
2004 $0.002 0.00%
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
2026 (TTM) $0.05 -44.44%
2025 $0.09 50.00%
2024 $0.06 -25.00%
2023 $0.08 -20.00%
2022 $0.1 150.00%
2021 $0.04 -33.33%
2020 $0.06 0.00%
2019 $0.06 12.57%
2018 $0.0533 -23.86%
2017 $0.07 55.56%
2016 $0.045 50.00%
2015 $0.03 -53.85%
2014 $0.065 30.00%
2013 $0.05 25.00%
2012 $0.04 -50.00%
2011 $0.08 0.00%
2010 $0.08 77.78%
2009 $0.045 3.93%
2008 $0.0433 -27.83%
2007 $0.06 33.33%
2006 $0.045 -64.00%
2005 $0.125 525.00%
2004 $0.02 0.00%
Pagos de dividendos de empresas similares o competidoras